In conclusion, findings from this study suggest the pharmacological downregulation of BBB-suited P-gp and BCRP could disrupt the BBB function and increase Aβ brain accumulation and thus have the potential to increase the risk of AD and CAA. Here, PGP is linked to Alzheimer disease.